Additionally, a study analyzed AXL expression in tumor specimens of metastatic ccRCC patients treated with Nivolumab following antiangiogenic therapy failure, revealing that high AXL expression correlated with lower treatment response rates and shorter progression-free survival. The gene discussed is AXL; the disease is nonpapillary renal cell carcinoma.